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John S. Rumsfeld, MD, PHD, FACCR andomized controlled trials (RCTs) remain a“gold standard” for evaluating treatmentefﬁcacy. Typically conducted in controlled
environments with selected populations, RCTs can
isolate the effect of a treatment on an outcome and
largely eliminate confounding. Thus, positive RCTs,
in the words of the philosopher Nancy Cartwright,
support the claim that the studied treatment “works
somewhere” (1). However, the results of RCTs alone
are not sufﬁcient to inform clinical practice decisions.
We need to know if the studied treatments “will work
for us” (1).
Will RCT interventions produce the desired out-
comes in our own practice situation and among the
patients we treat? RCT results are typically consid-
ered as a summary effect of the intervention among
the study participants, and heterogeneity of this
effect among individual patients is well characterized
(2). In addition, the selected trial populations may not
represent the typical population encountered in
clinical practice, further complicating the translation
of trial evidence to practice. Cartwright characterizes
this challenge as a need to understand the “capacity”
of the treatment, or its ability to reliably promote the
outcome across the spectrum of circumstances and
patients that we encounter in day-to-day practice.
Evaluating the potential for RCT ﬁndings to translateon, DC.to cardiovascular clinical practice is not consistently
done, and such information is usually slow to emerge.
To address this issue, the National Cardiovascular
Data Registry (NCDR) is launching the Rapid Registry
Response (RRR) initiative. The RRR initiative will use
clinical registry data to evaluate the implications of
RCT ﬁndings on current clinical practice in a timely
manner. Upon the release of important RCTs or new
clinical practice guidelines, the RRR initiative will be
poised to rapidly conduct analyses to determine their
effect on care. These analyses will address questions
such as the proportion of current patients in cardiol-
ogy practices that would have been eligible for
RCT enrollment, the size and characteristics of
patient populations that were not eligible for trial
enrollment, and prevalent comorbidities or other
treatments that may modify the RCT treatment. In
addition, insights from the initiative can also assist
cardiac researchers in formulating research hypothe-
ses for future studies. This ability of the initiative
to have practice inform evidence generation fulﬁlls
a fundamental component of “learning healthcare
systems” (3).
The RRR initiative will use the NCDR clinical reg-
istry programs to conduct these analyses. The NCDR
registries, which include a variety of cardiology con-
ditions and treatments, are some of the largest in the
world and, by virtue of their size, account for a sub-
stantial portion of U.S. cardiology practice. In addi-
tion, the 2 ambulatory registries, PINNACLE and the
Diabetes Collaborative Registry, capture data directly
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time assessment of the effect of new evidence on
current care. By using the NCDR programs to fuel its
analyses, the RRR initiative will provide comprehen-
sive and timely assessments of the capacity of RCTs
to translate to actual cardiology practice.
The recent IMPROVE-IT (IMProved Reduction of
Outcomes: Vytorin Efﬁcacy International Trial) pro-
vides an example of the potential of the RRR initia-
tive (4). The trial demonstrated a modest reduction in
cardiovascular events among patients with acute
coronary syndromes (ACS) receiving ezetimibe in
addition to a moderate-intensity statin (4). How do
the results of this study apply to current cardiovas-
cular practice? We can use NCDR PINNACLE data to
examine the proportion of patients that might have
been eligible for IMPROVE-IT enrollment, and thus
could potentially beneﬁt from the addition of ezeti-
mibe to their medication regimens. In addition, we
can determine the characteristics of those patients
currently on moderate-intensity statin therapy but
who would not have been eligible for the trial, to shed
light on where clinicians will have to make decisions
about whether trial results extrapolate to real-world
patient populations.
We can also consider the implications of the
IMPROVE-IT results on current practice. The most
recent cholesterol guidelines, published a year before
the release of the IMPROVE-IT trial results, recom-
mended high-intensity statins for all ACS patients (5).
In general, high-intensity statins achieve 20% addi-
tional lowering of low-density lipoprotein cholesterol
(LDL-C) levels relative to moderate-intensity statins.
This 20% additional reduction is very similar to the
effect that ezetimibe had on LDL-C lowering in
IMPROVE-IT. If, as the IMPROVE-IT investigatorscontend, the cardiovascular effect of ezetimibe was
primarily mediated by its LDL-C–lowering effects,
then its use in the setting of high-intensity statins
might result in even lower LDL-C levels than those
seen in the trial and, potentially, further reductions in
adverse cardiac events. An RRR analysis of current
statin practice patterns and the achieved LDL-C levels
with high-intensity statin use among patients with
ACS can provide insight into this possibility. Finally,
the registry can help identify the patient populations
that cannot tolerate high-intensity statins and that
might thus be the optimal candidates for ezetimibe,
or other lipid-lowering therapies such as PCSK9
inhibitors, as an adjunctive therapy.
Major RCTs and evidence syntheses with signi-
ﬁcant practice implications are released each year,
both at the major cardiology meetings (e.g., the
American College of Cardiology Scientiﬁc Sessions,
the American Heart Association Scientiﬁc Sessions,
and the European Society of Cardiology Congress)
and in the published medical data. The RRR initiative
will review this evidence and conduct complemen-
tary analyses to understand the capacity of this evi-
dence to inform current practice. Initial efforts are
already under way, with RRR analyses being con-
ducted in conjunction with several RCTs released at
the recent ACC Scientiﬁc Sessions. In this manner, the
RRR initiative will provide a timely “real-world”
perspective on the potential effect of the continually
evolving body of evidence to inform current cardio-
vascular practice.
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